{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:17:23Z","timestamp":1787231843200,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001998"],"award-info":[{"award-number":["UL1TR001998"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Results of a study to determine whether obesity is associated with acute kidney injury (AKI) among patients receiving combination therapy with piperacillin\u2013tazobactam and vancomycin are reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective, single-center cohort study of patients who received combination therapy for at least 48 hours was conducted using data from the University of Kentucky Center for Clinical and Translational Science\u2019s Enterprise Data Trust. Patients with chronic kidney disease, baseline creatinine clearance of less than 30 mL\/min, cystic fibrosis, or missing height or weight information were excluded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 8,125 patients were included in the cohort. Among the variables evaluated, total body weight of 91 kg or more was the variable most predictive of AKI. Patients with a weight of 91 kg or higher were more likely than lower-weight patients to have diabetes (39% versus 21%, p &lt; 0.00001), hypertension (64% versus 47%, p &lt; 0.00001), and heart failure (15% versus 13%, p = 0.007). The median daily vancomcyin dose was lower in patients with a weight of less than 91 kg (2,000 mg versus 3,000 mg, p &lt; 0.00001); however, weight-based doses were lower in patients weighing 91 kg or more (25.5 mg\/kg\/day versus 27.9 mg\/kg\/day, p &lt; 0.00001). AKI was more common in patients weighing 91 kg or more (24% versus 18%, p &lt; 0.00001; adjusted odds ratio, 1.46 [95% confidence interval, 1.28\u20131.66]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Increased total body weight increased the rate of AKI among patients concurrently treated with piperacillin\u2013tazobactam and vancomycin independent of clinically important confounders, with an important breakpoint occurring at 91 kg.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxz120","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T05:00:44Z","timestamp":1564635644000},"page":"1211-1217","source":"Crossref","is-referenced-by-count":19,"title":["Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin\u2013tazobactam and vancomycin"],"prefix":"10.1093","volume":"76","author":[{"given":"W Cliff","family":"Rutter","sequence":"first","affiliation":[{"name":"University of Kentucky College of Pharmacy, Lexington, KY, and University of Kentucky HealthCare, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"2nd","given":"Ronald G","family":"Hall","sequence":"additional","affiliation":[{"name":"Texas Tech University Health Sciences Center, Dallas, TX, and Dose Optimization and Outcomes Research (DOOR) program, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Burgess","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Pharmacy, Lexington, KY and University of Kentucky HealthCare, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"issue":"11","key":"2019080105003940500_CIT0001","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/jamainternmed.2016.5651","article-title":"Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012","volume":"176","author":"Baggs","year":"2016","journal-title":"JAMA Intern Med."},{"issue":"2","key":"2019080105003940500_CIT0002","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/516294","article-title":"Treatment of ventilator-associated pneumonia with piperacillin-tazobactam\/amikacin versus ceftazidime\/amikacin: a multicenter, randomized controlled trial. VAP study group","volume":"26","author":"Brun-Buisson","year":"1998","journal-title":"Clin Infect Dis."},{"issue":"2","key":"2019080105003940500_CIT0003","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0732-8893(97)00239-3","article-title":"Piperacillin\/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital","volume":"31","author":"Marra","year":"1998","journal-title":"Diagn Microbiol Infect Dis."},{"issue":"2","key":"2019080105003940500_CIT0004","doi-asserted-by":"crossref","first-page":"182.e1","DOI":"10.1016\/j.amjmed.2009.05.031","article-title":"Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?","volume":"123","author":"Hazlewood","year":"2010","journal-title":"Am J Med."},{"issue":"5","key":"2019080105003940500_CIT0005","first-page":"666","article-title":"Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam","volume":"64","author":"Hammond","year":"2017","journal-title":"Clin Infect Dis."},{"issue":"12","key":"2019080105003940500_CIT0006","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/phar.1851","article-title":"Is the combination of piperacillin-tazobactam and vancomycin associated with development of acute kidney injury? A meta-analysis","volume":"36","author":"Giuliano","year":"2016","journal-title":"Pharmacotherapy."},{"issue":"16","key":"2019080105003940500_CIT0007","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1001\/jama.2018.3060","article-title":"Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016","volume":"319","author":"Hales","year":"2018","journal-title":"Jama."},{"key":"2019080105003940500_CIT0008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2050-6511-14-12","article-title":"Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study","volume":"14","author":"Hall","year":"2013","journal-title":"BMC Pharmacol Toxicol."},{"issue":"4","key":"2019080105003940500_CIT0009","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"2019080105003940500_CIT0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis."},{"issue":"6","key":"2019080105003940500_CIT0011","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/17512433.2018.1471984","article-title":"Impact of total body weight on acute kidney injury in patients with gram-negative bacteremia","volume":"11","author":"Hall","year":"2018","journal-title":"Expert Rev Clin Pharmacol."},{"issue":"5","key":"2019080105003940500_CIT0012","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1128\/AAC.00028-12","article-title":"Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients","volume":"56","author":"Gauthier","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"2019080105003940500_CIT0013","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jinf.2012.01.015","article-title":"Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy","volume":"65","author":"Kubin","year":"2012","journal-title":"J Infect."},{"issue":"2","key":"2019080105003940500_CIT0014","first-page":"e02089","article-title":"Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime","volume":"2017","author":"Rutter","journal-title":"Antimicrob Agents Chemother."},{"key":"2019080105003940500_CIT0015","author":"Pharmacy Services, UK HealthCare"},{"issue":"6","key":"2019080105003940500_CIT0016","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol."},{"issue":"7","key":"2019080105003940500_CIT0017","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1592\/phco.31.7.658","article-title":"Estimating creatinine clearance: a meta-analysis","volume":"31","author":"Wilhelm","year":"2011","journal-title":"Pharmacotherapy."},{"key":"2019080105003940500_CIT0018","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Automat Contr."},{"key":"2019080105003940500_CIT0019","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure\u2013-definition, outcome, measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care."},{"key":"2019080105003940500_CIT0020","author":"RStudio Team. RStudio: integrated development for","year":"2015"},{"key":"2019080105003940500_CIT0021","author":"R Foundation for Statistical Computing. R: a language and environment for statistical computing.","year":"2014"},{"issue":"1","key":"2019080105003940500_CIT0022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/sim.5525","article-title":"Standardizing the power of the Hosmer-Lemeshow goodness of fit test in large data sets","volume":"32","author":"Paul","year":"2013","journal-title":"Stat Med."},{"issue":"7","key":"2019080105003940500_CIT0023","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/phar.1428","article-title":"Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime","volume":"34","author":"Gomes","year":"2014","journal-title":"Pharmacotherapy."},{"issue":"5","key":"2019080105003940500_CIT0024","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/phar.1738","article-title":"Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: a retrospective cohort study","volume":"36","author":"Hammond","year":"2016","journal-title":"Pharmacotherapy."},{"issue":"7","key":"2019080105003940500_CIT0025","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1060028018757497","article-title":"Comparison of the nephrotoxicity of vancomycin in combination with cefepime, meropenem, or piperacillin\/tazobactam: a prospective, multicenter study","volume":"52","author":"Mullins","year":"2018","journal-title":"Ann Pharmacother."},{"issue":"6","key":"2019080105003940500_CIT0026","doi-asserted-by":"crossref","first-page":"O384","DOI":"10.1111\/1469-0691.12410","article-title":"Acute renal failure associated with vancomycin and \u03b2-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime","volume":"20","author":"Moenster","year":"2014","journal-title":"Clin Microbiol Infect."},{"key":"2019080105003940500_CIT0027","doi-asserted-by":"crossref","first-page":"e00871","DOI":"10.1128\/AAC.00871-17","article-title":"Influence of \u03b2-lactam infusion strategy on acute kidney injury","volume":"61","author":"Cotner","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/16\/1211\/29026149\/zxz120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T23:42:23Z","timestamp":1569282143000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/76\/16\/1211\/5542364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":27,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz120","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,15]]},"published":{"date-parts":[[2019,8,1]]}}}